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Abstract
Duchenne muscle dystrophy (DMD) is a genetic disorder characterized by progressive skeletal muscle weakness.
Dystrophin deﬁciency induces instability of the sarcolemma during muscle contraction that leads to muscle necrosis
and replacement of muscle by ﬁbro-adipose tissue. Several therapies have been developed to counteract the ﬁbrotic
process. We report the effects of nintedanib, a tyrosine kinase inhibitor, in the mdx murine model of DMD. Nintedanib
reduced proliferation and migration of human ﬁbroblasts in vitro and decreased the expression of ﬁbrotic genes such
as COL1A1, COL3A1, FN1, TGFB1, and PDGFA. We treated seven mdx mice with 60 mg/kg/day nintedanib for 1 month.
Electrophysiological studies showed an increase in the amplitude of the motor action potentials and an improvement
of the morphology of motor unit potentials in the animals treated. Histological studies demonstrated a signiﬁcant
reduction of the ﬁbrotic areas present in the skeletal muscles. Analysis of mRNA expression from muscles of treated
mice showed a reduction in Col1a1, Col3a1, Tgfb1, and Pdgfa. Western blot showed a reduction in the expression of
collagen I in skeletal muscles. In conclusion, nintedanib reduced the ﬁbrotic process in a murine model of
dystrophinopathy after 1 month of treatment, suggesting its potential use as a therapeutic drug in DMD patients.
Introduction
Duchenne muscle dystrophy (DMD) is a genetic dis-
order produced by mutations in the dystrophin gene.
DMD patients develop muscle weakness that usually
starts at an age of 5–7 years and progresses quickly. At
14 years of age, most of the patients have lost ambulation.
At 20 years, patients are completely dependent on care
givers or relatives owing to severe muscle weakness.
Respiratory muscle failure and/or myocardiopathy are
the main causes of mortality in these patients1,2.
Several therapeutic strategies have been tested in mur-
ine models of DMD, and some of them have also been
studied in clinical trials in patients3. Cell therapy using
different stem cells, such as myoblasts or mesoangioblasts,
have been tested both in animals and in patients4.
Although results of animal experiments have shown
promising results, tests in humans have not lead to any
functional change in the patients treated5,6. Gene-based
strategies, such as exon-skipping or readthrough of null
mutations have demonstrated to restore the expression
of dystrophin in muscles ﬁbers both in mice and in
patients7,8. Ataluren is at present commercialized in
Europe to treat patients with non-sense mutations, and
eteplirsen is being commercialized in USA to treat DMD
patients with skipping of the exon 519,10. CRISPR-Cas9
is a promising genetic strategy, that could be useful in
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patients although it has only been tested in animal models
and cell cultures so far11,12. Drugs interfering the process
of muscle degeneration are another potential strategy to
treat muscle dystrophies. The process of muscle degen-
eration in DMD patients has been thoroughly studied.
The absence of dystrophin weakens muscle membrane,
leading to contraction-induced muscle ﬁber damage
and death13. Muscle ﬁber loss is associated to expansion
of ﬁbro-adipose tissue producing muscle weakness14.
Several cytokines and growth factors have been related
to skeletal muscle ﬁbrosis, although it has been reported
that transforming growth factor β (TGF-β) is the most
important factor in this process15–17. Several therapeutic
strategies trying to decrease TGF-β activity have been
developed, which have been shown to reduce ﬁbrous
tissue but also to increase inﬂammatory inﬁltration18,19.
These results have promoted the investigation of other
growth factors involved in muscle ﬁbrosis.
Platelet-derived growth factors (PDGFs) are associated
with multiple cellular processes such as proliferation,
migration, and cell differentiation20. PDGF have been
implicated in a broad range of diseases such as cancer,
atherosclerosis and ﬁbrosis. Several evidences supporting
a role on muscle ﬁbrosis of PDGF-AA have been pub-
lished justifying therapeutic interventions targeting
the PDGF signaling cascade21,22. Nintedanib is a tyrosine
kinase inhibitor (TKI) also targeting ﬁbroblast growth
factor receptor (FGFR) 1 and 2, PDGF receptors α
and β and vascular endothelial growth factor receptor
(VEGFR)23. Nintedanib is approved for the treatment
of patients with idiopathic pulmonary ﬁbrosis (IPF), a
condition in which expansion of the ﬁbrotic tissue is
crucial24,25. The anti-ﬁbrotic activity of nintedanib has
been conﬁrmed in primary lung ﬁbroblasts from patients
with IPF and in dermal ﬁbroblasts from patients with
systemic sclerosis25,26.
In this study, we explored the effect of nintedanib on
human ﬁbroblasts obtained from muscle biopsies and
on muscle ﬁbrosis and function in the mdx mouse model
of DMD.
Results
Nintedanib reduced proliferation, migration, and mRNA
expression of ﬁbrotic markers in human ﬁbroblasts
In muscle dystrophies, activated ﬁbroblasts proliferate
and express high levels of extracellular proteins leading
to the expansion of ﬁbrotic tissue27,28. We analyzed
whether nintedanib was able to decrease ﬁbroblast
proliferation in vitro. Nintedanib signiﬁcantly reduced
ﬁbroblast proliferation in a dose-dependent manner
reaching the highest effect using a concentration of 0.4 μM
(Fig. 1a) without any cytotoxic effect measured by cell
viability and apoptosis assays (Fig. S1A, B). Accordingly,
the expression of the gene PT53 (tumor protein p53) and
the number of Ki-67+ cells, which are well known cell
cycle markers, were signiﬁcantly lower in nintedanib-
treated cells than in control non-treated cells (Fig. S1C, D).
To study which growth factor signaling cascade targeted
by nintedanib affects more prominently ﬁbroblasts pro-
liferation, we cultured human ﬁbroblasts in the presence
of recombinant PDGF-AA, recombinant human basic
ﬁbroblast growth factor (bFGF), or recombinant human
vascular endothelial growth factor (VEGF)-A, with or
without nintedanib (Fig. 1b–d). In order to avoid possible
interferences with other growth factors present in the fetal
bovine serum (FBS), we cultured the cells with 1% FBS
only. PDGF-AA signiﬁcantly increased ﬁbroblast pro-
liferation at days 2, 4, and 6 (Fig. 1b) but not bFGF
or VEGF (Fig. 1c, d). This increase was completely blocked
by the addition of nintedanib at 0.4 μM (Fig. 1b).
After muscle damage, activated ﬁbroblasts gain migra-
tory capabilities that allow them to move to the site of
injury29,30. Using a scratch assay, we observed that nin-
tedanib blocked cell migration promoted by PDGF-AA,
bFGF, VEGF, and collagen tissue growth factor (CTGF)
(Fig. 1e). The highest effect of nintedanib on cell migra-
tion was observed when PDGF-AA was added to the
culture (Fig. 1e, f) and it was dose dependent (Fig. S2A, B).
Transwell experiments conﬁrmed these results showing
that nintedanib reduced the effect of PDGF-AA in
migration (Fig. S2C). Furthermore, nintedanib reverted
signiﬁcantly the effect of PDGF-AA on expression of the
genes related with cell migration such as ADAM-17
(ADAM metallopeptidase domain 17), TIMP-1 (tissue
inhibitor of metalloproteinase 1), and TIMP-2 (tissue
inhibitor of metalloproteinase 2) (Fig. 1g). No signiﬁcant
differences were found in ADAM-12 (ADAM metallo-
peptidase domain 12), MMP1 (metalloproteinase 1),
MMP2 (metalloproteinase 2), and MMP9 (metallopro-
teinase 9) (Fig. 1g). To know whether nintedanib treat-
ment modiﬁed mRNA expression of skeletal muscle
ﬁbroblasts in vitro we analyzed the expression of genes
related with muscle ﬁbrosis using Real-Time PCR after
4 days of culture. We observed that nintedanib at 0.4 μM
reduced signiﬁcantly the expression of COL1A1 (Collagen
type I alpha 1 chain), COL3A1 (collagen type III alpha 1
chain), FN1 (Fibronectin 1), CTGF (connective tissue
growth factor), PDGFA (platelet-derived growth factor A),
and TGFB1 (transforming growth factor beta 1) (Fig. 1h).
In contrast, we did not observe signiﬁcant differences in
the expression of ACTA-2 (actin, alpha 2, smooth muscle,
aorta) or PDGF-B (platelet-derived growth factor B).
Nintedanib had no effect on myoblast differentiation to
myotubes in vitro
To analyze whether nintedanib could interfere with
myoblast differentiation we cultured conﬂuent human
myoblasts in differentiation medium with increasing
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doses of nintedanib for 7 days. No differences in differ-
entiation index between control myotubes and myotubes
treated with nintedanib were observed (Fig. S3A). In
addition, we did not ﬁnd differences in the differentiation
index of myoblasts cultured in a medium containing
PDGF-AA, b-FGF, or VEGF-A with or without nintedanib
(Fig. S3B, C). We also studied whether myotubes treated
with nintedanib were more resistant to chemical damage
using 0.25 mM sodium dodecyl sulfate (SDS), and we
did not see an effect of nintedanib on sarcolemma repair
(Figure S3D).
Nintedanib treatment improves electrophysiological tests
in mdx mice
We treated 10 months old mdx mice (n= 7) with nin-
tedanib (from now on nintedanib-treated mdx mice) at a
Fig. 1 Effect of nintedanib on ﬁbroblasts from healthy human muscle in vitro. Fibroblasts proliferation was analyzed after 2, 4, and 6 days
of culture (a–d). We cultured ﬁbroblast with increasing concentrations of nintedanib in a culture containing 10% fetal bovine serum (FBS) and
we observed decreased ﬁbroblast proliferation after 4 and 6 days in a dose-dependent manner (a). Fibroblasts were cultured in the presence of
platelet-derived growth factor AA (PDGF-AA, 10 ng/mL) (b), basic ﬁbroblast growth factor (FGFb, 10 ng/mL),(c) or vascular endothelial growth factor
A (VEGF-A, 50 ng/mL) (d) with 1% FBS with or without nintedanib 0.4 μM. Only PDGF-AA increased cell proliferation, an effect that was reversed with
the addition of nintedanib to the culture. Fibroblast migration was analyzed using a scratch assay. Nintedanid treatment at 0.4 μM reverted the
promigratory effect of PDGF-AA, FGFb, VEGF, and CTGF (e). Representative images of this assay are shown in (f). Nintedanib treatment at 0.4 μM
(blue bars) reverted the effect of PDGF-AA in the expression of ADAM metallopeptidase domain 17 (ADAM-17), tissue inhibitor of metalloproteinase 1
(TIMP-1) and tissue inhibitor of metalloproteinase 2 (TIMP-2) (g). Nintedanib treatment at 0.4 μM (blue bars) produced a statistically signiﬁcant
reduction of collagen type I alpha 1 chain (COL1A1), collagen type III alpha 1 chain (COL3A1), ﬁbronectin 1 (FN1), platelet-derived growth factor A
(PDGFA), connective tissue growth factor (CTGF), transforming growth factor beta 1 (TGFβ1) expression compared with control samples (black bars)
analyzed by qPCR (h). Data are expressed as means ± SD. N= 3 per group. *P < 0.05, **P < 0.01, ***P < 0.005
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dose of 60 mg/kg/day orally for 1 month and compared
muscle function tests with 10 months old non-treated
mdx mice (from now on mdx mice; n= 5) and 10 months
old C57 wild-type mice (from now on WT mice; n= 5).
We ﬁrst performed a DigiGait analysis, which allows
identifying differences in the walking pattern of healthy
and dystrophic mice. We did not ﬁnd differences between
WT mice, mdx mice, and nintedanib-treated mdx mice,
suggesting that the severity of weakness involving muscles
of the paws in this murine model at this age is not enough
to ﬁnd differences using this technique (Fig S4).
We then used electrophysiological tests to analyze
compound muscle action potential (CMAP) amplitude
and morphology of the motor unit action potentials
(MUAPs). We detected a statistically signiﬁcant increase
of the CMAP of the peroneus nerve registered at the
tibialis anterior muscle in nintedanib-treated mdx mice
compared with mdx mice (Fig. 2a). Moreover, we also
found a non-signiﬁcant tendency to an increase of
CMAPs recorded in gastrocnemius (GM) and plantar
interossei muscles (Fig. 2b, c). We did not identify chan-
ges in latency or conduction velocity. Electromyographic
studies showed a signiﬁcant change in the morphology of
the MUAPs in the tibialis anterior muscle. WT muscles
contained a similar proportion of small and medium
MUAPs, whereas mdx mice had predominantly small
MUAPs. The analysis of nintedanib-treated mdx mice
revealed a signiﬁcant decrease in the proportion of small
MUAPs and an increase in the proportion of medium and
large MUAPs, which was statistically signiﬁcant compared
with mdx mice (Fig. 2d–g).
Nintedanib treatment reduces muscle ﬁbrosis in mdx mice
The analysis of muscle histology after 1 month of
treatment revealed signiﬁcant differences between
nintedanib-treated and non-treated mdx mice without
any effect on apoptosis in the muscle of the animals
(Fig. S5). We analyzed the diaphragm, which has been
reported to be the most affected muscle in mdx mice31,
the quadriceps and the tibialis anterior of WT, mdx mice,
Fig. 2 Motor nerve conduction tests and electromyographic analysis of WT, mdx, and nintedanib-treated mdx mice after 4 weeks of
treatment. a–c Motor nerve conduction test showed that nintedanib administration preserved the compound muscle action potential (CMAP) i`n
the tibialis anterior (a), gastrocnemius (b), and plantar (c) muscles. d, e Electromyography (EMG) of tibialis anterior. AUC quantiﬁcation of
electromyography (EMG) responses of the TA muscle after application of Von Frey ﬁlaments 5.47 to the ipsilateral hind paw (d). Percentage of MUAPs
from each type that were activated (e) and EMG showed a lower proportion of small pathologic motor unit action potentials (MUAPs) in nintedanib-
treated mdx mice. f–h Representative recordings of EMG bursts after nociceptive stimuli in WT (f), mdx (g), and nintedanib-treated mdx mice (h).
Note that mdx animals showed lower amplitude and shorter duration MUAPs compared with WT and nintedanib-treated mdx mice. Data are
expressed as means ± SD. Genetic background mouse strain C57BL (WT); n= 5, mdx mice (mdx), n= 5; nintedanib-treated mdx mice (mdx+ Ninte.),
n= 7. Data are expressed as means ± SD. *P < 0.05, **P < 0.01, **** p < 0.0001
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and nintedanib-treated mdx mice. Hematoxilin–eosin
staining showed no differences either on the size of the
muscle ﬁbers or in the proportion of central nucleated
ﬁbers between mdx mice and nintedanib-treated mdx
mice (Fig. 3). As nintedanib blocks the VEGF receptor,
we also analyzed muscle vascularization. Although we did
not ﬁnd differences in the ratio of CD31-positive vessels
per ﬁber among the three groups of mice, nintedanib
treatment tended to reverse the increase observed in
the ratio vessels/muscle ﬁbers observed in the mdx
mice (Fig.S6). To investigate in vivo the effect of ninte-
danib in the muscle, we quantiﬁed the number of eMHC-
positive muscle ﬁbers, which is an early marker of muscle
regeneration. We observed a decrease in the number of
muscle ﬁbers expressing eMHC, in nintedanib-treated
mdx mice compared with mdx mice (Fig. 4). We then
analyzed the area of ﬁbrotic tissue present in the skeletal
muscles by quantifying collagen VI expression (Fig. 5).
We observed a statistically signiﬁcant reduction in the
collagen VI area in the diaphragm (−5.6%), the quad-
riceps (−8.4%) and in the tibialis anterior muscles
(−4.1%) of nintedanib-treated mdx mice compared with
mdx mice (Fig. 5).
The mRNA expression of the extracellular matrix
proteins Col1a1, Col3a1, and Fn1, of the growth
factors Pdgfa, Pdgfb, Ctgf, and Tgfb1, and of Adgre1
(Adhesion G protein-coupled receptor E1) encoding
F4/80, a protein expressed by murine macrophage
populations, were signiﬁcantly increased or showed a
tendency to increase in mdx mice compared with WT
mice (Fig. 6). The mRNA expression of Col1a1, Col3a,
Tgfb1, Pdgfa, and Pdgfb in quadriceps (Fig. 6d, e),
diaphragm (Fig. 6l, m), and tibialis anterior muscles
(Fig. 6t, u) of nintedanib-treated mdx mice was reduced
compared with mdx mice. Adgre1 mRNA expression was
decreased by nintedanib in tibialis anterior and quad-
riceps muscles (Fig. 6o, r, w, y) from nintedanib-treated
mdx mice compared with mdx mice. Surprisingly, ninte-
danib signiﬁcantly increased Ctgf in the tibialis anterior
muscles of mdx mice (Fig. 6v). A similar trend was also
detected in the other muscles.
We conﬁrmed the reduced expression of Col1a1 and
Col3a1 by WB, with a signiﬁcant decrease of collagen-1
in the tibialis anterior (p < 0.05) and a trend in the
diaphragm (p= 0.08) of nintedanib-treated mdx mice
compared with mdx mice (Fig. 7).
Effect of nintedanib in heart ﬁbrosis of the mdx mouse
We quantiﬁed the collagen VI and collagen III content
in heart sections of WT, mdx mice, and nintedanib-
treated mdx mice. We did not observe a signiﬁcant dif-
ference in the area positive for collagen VI between WT
and non-treated mdx mice (Fig. S7A–D). In contrast,
collagen III was increased in mdx mice but it was not
Fig. 3 Histological analysis of muscle samples of WT, mdx and nintedanib-treated mdx mice. Hematoxylin and eosin (H&E) staining of
muscle samples obtained (a–i). Representative examples of cross-sectional muscle ﬁbers within quadriceps (a–c), diaphragm (d–f), and tibialis
anterior (g–i) of WT, mdx and nintedanib-treated mdx mice. Schematic representation of the ﬁber mean area in quadriceps (j), diaphragm (k), and
tibialis anterior (l) showed no differences on the size of the muscle ﬁbers. Analysis of the proportion of central nucleated ﬁbers in quadriceps (m),
diaphragm (n), and tibialis anterior (o) did not present signiﬁcant differences after 1 month of treatment with nintedanib (60 mg/kg). Data are
expressed as means ± SD. Genetic background mouse strain C57BL (WT); n= 5, mdx mice (mdx), n= 5; nintedanib-treated mdx mice (mdx+ Ninte),
n= 7. Data are expressed as means ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001. Scale bar= 100 µm
Piñol-Jurado et al. Cell Death and Disease  (2018) 9:776 Page 5 of 15
Ofﬁcial journal of the Cell Death Differentiation Association
modiﬁed by nintedanib (Fig. S7E–H). However, gene
expression showed a signiﬁcant decrease in the Col3a1
mRNA expression in nintedanib-treated mdx mice
compared with non-treated mdx (Fig. S7J). mRNA
expression of the Col1a1, Fn1, Pdgfa, Pdgfb, Ctgf, Tgfb1,
and of Adgre1 was also studied. We only observed a
decrease in the expression of the Adgre1 gene after
treatment with nintedanib (Fig. S7I–P).
Discussion
In the present study, we show that nintedanib reduces
skeletal muscle ﬁbrosis of 10 months old mdx mice
after 4 weeks of treatment. The decrease in ﬁbrotic tissue
was associated with an improvement of muscle function
evidenced by electrophysiological tests. In vitro experi-
ments showed that nintedanib decreased ﬁbroblasts
proliferation and migration and reduced expression of
ﬁbrotic genes, supporting an anti-ﬁbrotic effect of
the drug.
Pharmacological approaches to treat muscle dystrophies
aim to target the complex mechanism of ﬁber necrosis
and ﬁbrotic and fatty tissue deposition by restoring
the proper expression of the mutated gene or by inter-
fering with the pathological ﬁbrotic cascade triggered
by the lack of speciﬁc proteins32. Advances in the
understanding of the ﬁbrotic process have been recently
achieved33,34. Continuous muscle ﬁber damage is asso-
ciated with chronic inﬁltration of skeletal muscles by
inﬂammatory cells, mainly macrophages. These cells
release cytokines that contribute to the ﬁbrotic process by
activating ﬁbro-adipogenic progenitor cells and ﬁbro-
blasts resident in the skeletal muscle22,35. Among these
cytokines, the growth factors of the PDGF family may
have an important role. A series of evidences from the
literature suggest that PDGF-AA has a proﬁbrotic role
in muscle dystrophies35–39. Treatment of mdx mice with
imatinib, a TKI inhibiting v-Abl, c-kit, and PDGFRα,
decreases muscle ﬁbrosis40. The role of PDGF-BB is not
so clearly established. Whereas it seems that PDGF-BB
could have a role in the ﬁbrosis observed in a number of
tissues, several authors suggest that it can also play an
important role in muscle regeneration in vivo41,42.
Nintedanib was shown to inhibit ﬁbroblast proliferation
and migration in vitro and to exert anti-ﬁbrotic activity
in different animal models of lung ﬁbrosis25,26. We
observed that muscle ﬁbrosis was reduced in mdx
mice after 4 weeks of treatment with nintedanib. This
effect is probably explained by a decreased rate of ﬁbro-
blasts proliferation, migration and by a reduction of
the expression of different components of the extra-
cellular matrix. Skeletal muscle ﬁbrosis in DMD is caused
by accumulation of different types of collagens, such as
Fig. 4 Nintedanib reduced the number of regenerative muscle ﬁbers in mdx mice. Immunostaining of eMHC and quantiﬁcation of positive
ﬁbers in muscle samples of WT, mdxand nintedanib-treated mdx mice (a-l). The number of eMHC-positive ﬁbers (green) is reduced in quadriceps,
diaphragm and tibialis anterior in mdx mice treated with nintedanib. Background in red is shown to localize the positivity within the muscle.
Data are expressed as means ± SD. *P < 0.05 and **P < 0.01. Scale bar= 100 µm
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type I, III, and VI and also by ﬁbronectin. We focused
on collagen VI and III because they are the major com-
ponents of the extracellular matrix and their levels cor-
relates with muscle destruction31,36,43,44. We have
observed a reduction in the expression of these extra-
cellular matrix components both in vivo and in vitro.
Moreover, we also observed a decrease in the expression
of proﬁbrotic growth factors such as PDGF-AA or TGF-β,
which can certainly contribute to an attenuation of the
ﬁbrotic process in the treated mice. However, we observed
an increase in CTGF levels in muscles of nintedanib-
treated mdx mice, which could be explained by an
enhanced ﬁbrotic pathway not inhibited by our drug. This
effect suggests that treatment with a combination of drugs
blocking different pathways could have a more powerful
anti-ﬁbrotic effect. Using cell culture conditions with
only 1% FBS, ﬁbroblast proliferation was stimulated
most prominently by PDGF-AA compared with VEGF
or bFGF, which had no effect in those culture conditions.
Hence, drugs targeting PDGFRα, the main receptor acti-
vated by PDGF-AA may be useful in the treatment of
muscle dystrophies.
The preclinical investigation of new drugs to treat DMD
is hampered by the lack of an animal model, which
mimics the severity of muscle degeneration and natural
history of the disease in patients. In the mdxmouse model
we used, it has been shown that signiﬁcant changes in
muscles cannot be observed until 8–10 months of age45.
Moreover, despite the presence of clear myopathic
changes, mice do not present functional impairment until
later in their life. Similar ﬁndings would apply to heart
involvement. This might explain the absence of differ-
ences that we have observed in the Digigait test when
comparing healthy C57 mice and non-treated mdx mice.
Electrophysiology is an objective test that does not need
the collaboration of the mice, providing valuable data
about muscle integrity46. We observed signiﬁcant changes
in the amplitude of the CMAPs and in the morphology
of the MUAPs using electrophysiological tests that were
restored with treatment. These results are probably
the consequence of early changes in the muscle structure
produced by nintedanib that occur before clinical
symptoms are observed.
The effect of speciﬁc TKIs, such as nintedanib, on the
amount of ﬁbrotic tissue present in the skeletal muscles
of the patients may also improve muscle homeostasis.
It is well known that muscle microenvironment is
important for proper tissue regeneration47. In the process
Fig. 5 Nintedanib reduced skeletal muscle ﬁbrosis in mdx mice. Representative pictures of immunoﬂuorescence staining for collagen VI in
quadriceps (a–c), diaphragm (d–f), and tibialis anterior (g–i) of WT, mdx, and nintedanib-treated mdx mice. Endomysial collagen deposition
increased in all mdx muscles compared with WT group and decreased in nintedanib-treated mdx muscles, signiﬁcantly in quadriceps (j) and
diaphragm (k) but not in tibialis anterior (l) compared with non-treated mdx mice. Data are expressed as means ± SD. Genetic background mouse
strain C57BL (WT); n= 5, mdx mice (mdx), n= 5; nintedanib-treated mdx mice (mdx+ Ninte), n= 7. *P < 0.05. Scale bar of quadriceps and tibialis
anterior= 200 µm. Scale bar of diaphragm= 100 µm.
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Fig. 6 (See legend on next page.)
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of muscle degeneration, there is an imbalance between
proregenerative and prodegenerative processes. The
increase in ﬁbro-adipous tissue and the presence of
chronic inﬂammation seem to impinge satellite cell pro-
liferation, differentiation, and eventually muscle regen-
eration48,49. We hypothesize that nintedanib treatment
could have a double beneﬁt: (1) it reduces the amount of
ﬁbrotic tissue and (2) it could indirectly, restore the
balance between proregenerative and prodegenerative
processes. Our results support this hypothesis. We
observed that nintedanib did not interfere with the dif-
ferentiation ability of myoblasts in vitro or the resistance
of myotubes to chemical damage. However, we did not
see an increase in the number of regenerative muscle
ﬁbers in the animals treated suggesting that a reduction
of the ﬁbrotic process preserves skeletal muscle structure.
Indeed, electromyograhy (EMG) studies showing
restoration of MUAPs morphology indicate that muscle
structure is more preserved in the treated animals sup-
porting this hypothesis. It is important to take into
account that we have observed a reduction of ﬁbrotic
tissue in an old animal, in which the ﬁbrotic process has
already developed. Treatment of younger animals for
longer periods of time could result in a more sustained
effect, although this needs to be conﬁrmed in further
experiments.
(see ﬁgure on previous page)
Fig. 6 RT-qPCR studying mRNA expression of ﬁbrosis-related genes. Collagen type I alpha 1 chain (Col1a1), Collagen type III alpha 1 chain
(Col3a1), Fibronectin 1 (Fn1), Platelet-derived growth factor A (Pdgfa), Platelet-derived growth factor B (Pdgfb), Connective tissue growth factor (Ctgf),
Transforming growth factor beta 1 (Tgfβ1), and Adhesion G protein-coupled receptor E1 (Adgre1) showed changes in relative abundance following
nintedanib in quadriceps (a–h), diaphragm (i–p), and tibialis anterior (q–y). Col1a1, Col3a1, Pdgfa, Tgfb1, and Adgre1 gene expression was increased in
mdx mice compared with WT. Col1a1, Col3a1, Pdgfa, Pdgfb, Tgfb1, and Adgre1 expression was reduced in all muscles analyzed from nintedanib-
treated mdx mice compared with mdx mice. In contrast, Ctgf expression was increased in muscles from nintedanib-treated mdx mice compared with
mdx mice. Data are expressed as means ± SD. Genetic background mouse strain C57BL (WT); n= 5, mdx mice (mdx), n= 5; nintedanib-treated mdx
mice (mdx+ Ninte), n= 7. *P < 0.05, **P < 0.01, ***P < 0.005
Fig. 7 Nintedanib decreased collagen I expression in mdx muscles. Western blotting of Collagen I in quadriceps (a), diaphragm (b), and tibialis
anterior (c) showed a reduction in the protein expression in diaphragm (e) and tibialis anterior (f) but not in quadriceps (d) of nintedanib-treated mdx
mice compared with mdx mice by quantiﬁcation of Collagen I normalized to α-tubulin levels. Data are expressed as means ± SD. Genetic background
mouse strain C57BL (WT); n= 4, mdx mice (mdx), n= 4; nintedanib-treated mdx mice (mdx+ Ninte), n= 4. *P ≤ 0.05 and **P ≤ 0.01
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Different TKIs have been recently tested in murine
models of muscle dystrophy. Imatinib has been tested
in the mdx model producing a reduction in ﬁbrotic
tissue and in muscle ﬁber necrosis21,40,50. However,
this drug, that is commonly used as a therapy for
chronic myeloid leukemia and gastrointestinal tumors, is
potentially associated with cardiac toxicity51–53. Nilotinib
has been shown to reduce ﬁbrosis in the mdx model
through a mechanism related to the activation of
apoptosis of FAP cells mediated by TGF-β 43. Nilotinib
has been approved for the treatment of chronic myeloid
leukemia and has been also tested in patients with
dermal ﬁbrosis54,55. Crenolanib is a TKI that inhibits
selectively PDGFRα being tested in phase II clinical trials
of gastrointestinal tumors56, melanomas57, or even acute
myeloid leukemia58. This drug was tested in the mdx
murine model and produced a reduction in collagen
expression in the diaphragm of mdx mice59. Our pro-
mising results reinforce the potential role of speciﬁc
TKIs such as nintedanib in the treatment of patients
with muscle dystrophies. Nintedanib seems advantageous
for a clinical exploration in DMD owing to its proven
anti-ﬁbrotic activity in patients with idiopathic
pulmonary ﬁbrosis, the fact that it has been approved
for clinical use and its good safety proﬁle24,25. However
clinical experience is only available in patients with
idiopathic pulmonary ﬁbrosis, which are much older
than patients with DMD. The potential impact of ninte-
danib as VEGFR inhibitor on bone and teeth formation
during development in childhood is a safety concern
that has to be carefully considered in a clinical testing
scenario60.
In summary, nintedanib attenuated the ﬁbrosis of
skeletal muscles of mdx mice and induced a functional
muscular improvement. The reduction of ﬁbroblast
proliferation and chemotaxis and the decreased expres-
sion of proﬁbrotic genes by nintedanib may explain
the mechanism of action of this drug. The data
presented in this proof of concept study should be
conﬁrmed in larger preclinical studies before supporting
a future test of nintedanib in a clinical trial in DMD
patients. However, because of the lack of experience
in young patients with nintendanib, a clinical trial to
test safety, tolerability, and efﬁcacy of the drug is
certainly challenging.
Material and methods
Muscle biopsies
Muscle biopsies were obtained from patients who
underwent orthopedic surgery. All participants signed an
informed consent form and all the procedures were
in accordance with the Helsinki Declaration. All in vitro
experiments were performed in ﬁbroblasts (proliferation,
migration, and mRNA expression studies) and myoblasts
(differentiation analysis) isolated from control muscle
biopsies (n= 3).
Isolation and culture of myoblasts and ﬁbroblasts from
human muscle biopsies
Human myoblasts and ﬁbroblasts were isolated from
muscle biopsies of three healthy muscles from control
donors. In brief, muscle biopsies were minced into 1–2
mm pieces, transferred onto collagen type I (Sigma, St.
Louis, MO)-coated dishes, and incubated in proliferation
medium containing Dulbecco's Modiﬁed Eagle's Medium
(DMEM) and M-199, in a 3:1 proportion, with 15% FBS, 2
mM L-glutamine (all from Lonza, Verviers, Belgium)
(Lonza), 5 ng/ml basic ﬁbroblast growth factor (Pepro-
tech, Rocky Hill, NJ), and 1% penicillin–streptomycin
(Lonza). After 5–7 days, cells started to sprout from
the muscle explants. We isolated myoblasts using anti-
CD56 coated microbeads (MiltenyiBiotec, Bergisch-
Gladbch, Germany) and conﬁrmed that the purity of
the samples was higher than 95% performing immuno-
ﬂuorescence with antibodies against CD56 and desmin.
Puriﬁed human myoblasts were cultured in proliferation
medium. Fibroblasts were isolated from the CD56-
negative fraction. We conﬁrmed that > 95% of them
were ﬁbroblasts using anti-TE7 antibody (Millipore,
Billerica, MA) by immunoﬂuorescence. Fibroblasts were
maintained in DMEM supplemented with 10% FBS,
2 mM glutamine, and 100 U/ml penicillin–streptomycin.
All experiments performed with myoblasts and ﬁbroblasts
were repeated with cells isolated from all patients (n= 3)
and were replicated in triplicate.
Differentiation and repair assay of human myotubes
Myoblasts were seeded in gelatin-coated cover slips,
grown until conﬂuence in proliferation media and then
cells were switched to low serum medium (2% of FBS)
to induce differentiation in the presence of increasing
doses of nintedanib (0.1, 0.2, 0.3, or 0.4 µM). In the
repair assay, different doses of Nintedanib were added
to untreated myotubes after 7 days of differentiation
and incubated overnight and 2 h prior to the assay to
ensure an effective inhibition of the TKI. After washing
with Hank’s Balanced Salt Solution (HBSS) (Lonza) we
added the injury solution (HBSS with 0.25 mM SDS
(Sigma) and 1.8 mM CaCl2 (Sigma)) for 2 min. Control
cells were treated with HBSS and 1.8 mM CaCl2 without
SDS. Then, cells were washed with HBSS+ 1.8 mM CaCl2
and incubated in recovery solution consisting of pro-
liferation media at two time points: 90 s and 10 min. After
that cells were exposed for 2 min to propidium iodide
(Sigma) (20 µg/ml in HBSS) that stains nuclear DNA
only if when the cell membrane is injured. Finally cells
were washed with HBSS, ﬁxed with 4% of paraformalde-
hyde (Sigma) in phosphate-buffered saline (PBS) and
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stained with Hoechst (100 µg/ml in PBS) (Invitrogen,
Carlsbad, CA). The total number of nuclei and
immunoprecipitation-positive nuclei were counted using
Fiji software.
Cell proliferation, viability, and cell death
To study the inﬂuence of nintedanib on cell pro-
liferation, we seeded ﬁbroblasts at 2000 cells/cm2 and
cultured in growth medium containing 15% FBS. In
these culture conditions, ﬁbroblasts were treated
daily with different concentrations of nintedanib (0.1,
0.2, 0.3, and 0.4 µM) (kindly provided by Boehringer-
Ingelheim, Ingelheim, Biberach, Germany). To know
which of the growth factors inhibited by nintedanib had
a signiﬁcant effect on ﬁbroblast growth we analyzed cell
proliferation on a medium that contained only 1% FBS.
We added to the medium 10 ng/ml PDGF-AA (R&D
Systems, Minneapolis, MN), 50 ng/ml VEGF-A (Pepro-
Tech, INC, Rocky Hill, NJ) or 10 ng/ml bFGF (Pepro-
Tech) with or without 0.4 µM nintedanib. Absolute
cell numbers and viability, using LIVE/DEAD viability/
cytoxicity kit (Invitrogen), were analyzed at days 2, 4,
and 6 using MACS ﬂow cytometer analyzer 10
(Miltenyi Biotech). Basal background was established
using non-stained cells. To analyze cell death we
performed a terminal deoxynucleotidyl transferase
dUTP nick end labeling assay in ﬁbroblasts treated
with nintedanib and in muscle sections from the animal
studies using in situ cell death detection kit (Sigma)
following the manufacturer’s instructions. DNase I
(Invitrogen) treatment was used as a positive control.
Scratch and transwell assays
Migration of human ﬁbroblasts was assessed using
a scratch assay. In brief, human ﬁbroblasts were
seeded in proliferation medium until 90% conﬂuence.
In one set of experiments medium was changed to
DMEM O/N, while in the other set, proliferation medium
was maintained. The day after, cultures were scratched
with a 0.2 ml pipette sterile tip to create a wound
and washed in PBS and photographed. We assessed the
effect of different doses of nintedanib (0.1, 0.2, 0.3,
and 0.4 μM) on cell migration of proliferating ﬁbroblasts
after 24 h. In the set of experiments containing
DMEM alone, nintedanib (0.4 μM) was incubated for
2 h. Then, PDGF-AA (20 ng/ml), TGFb (5 ng/ml),
CTGF (55 ng/ml), bFGF 10mg/ml, or VEGF (20 mg/ml)
were added, incubated for 24 h, and photographed.
Migration was quantiﬁed using Image J software. Inhibi-
tion of migration was expressed considering 100%
as the amount of migration in the conditions without
nintedanib. Three pictures of each replicate (n= 3) and
each condition were taken using an inverted microscope
(Olympus).
Transwell assays were performed in ﬁbroblasts treated
with or without 0.4 μM nintedanib for 2 h in a T75 ﬂask.
Then, cells were seeded into 8-μm pore-size transwell ﬁlters
(Corning Incorporated, Corning, NY) at 4 × 104 cells/well
in 200 μl of OPTIMEM. In total, 600 μl of OPTIMEM with
10 ng/mL PDGF-AA or vehicle was added to the lower
chamber. After 24 h of treatment at 37 °C, cells on the
topside of the ﬁlter were removed by scrubbing twice with
a cotton swab, and cells on the bottom side of the ﬁlter
and cells in the well (migrating cells) were counted. Cells
present in the insert membranes were ﬁxed with methanol
70% for 10min and stained for 30min with Hoechst
(Invitrogen). After three washes with PBS, ﬁlters were
cut, mounted onto a slide, and observed with an Olympus
ﬂuorescence microscope. Chemotaxis toward Opti-MEM
medium was considered as nonspeciﬁc chemotaxis.
Fibroblast gene expression
To study ﬁbroblasts mRNA expression, we seeded
3000 ﬁbroblasts per cm2 and cultured them in growth
medium. Fibroblasts were treated every 24 h with 0.4 μM
nintedanib for 4 days and cell pellets were snap frozen
with liquid nitrogen for the subsequent RNA processing.
Mouse model
All animal procedures were performed according to
the National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals and were approved
by the Ethical Committee of the Universitat Autònoma
de Barcelona. All mice used in the study were male
and 10 months old at the start of the treatment period.
Nintedanib was solubilized in sterile ultra-pure water
(Braun, Rubi, Spain) and delivered to the animals using
gavage. We treated seven C57BL/10ScSn-Dmdmdx mice
with 60 mg/kg of nintedanib once daily for 4 weeks. As
controls we used ﬁve untreated C57BL/10ScSn-Dmdmdx
mice and ﬁve C57BL healthy mice.
After treatment, motor functional and electro-
physiological studies were performed. Immediately after
functional studies, the animals were euthanized and the
diaphragm, tibialis anterior, quadriceps, and heart mus-
cles were collected and frozen.
Motor functional analysis: Digigait assay
Locomotion analysis was performed using the Digigait
Imaging system (Mouse Speciﬁcs, Quincy, MA). In brief,
digital video images of the underside of the mouse were
collected with a high-speed video camera (80 frames/s)
from below the transparent belt of a motorized treadmill.
Each mouse was allowed to explore the treadmill com-
partment, with the motor speed set to zero, for 5 min.
Then, the motor speed was set to 20 cm/s to collect the
videos. A minimum of 200 images was collected for each
walking mouse so that ﬁve to seven strides were captured
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in each run. Video images of 12.5 ms duration were
digitized and the area (in pixels) of the paws was calcu-
lated with the DigiGait software.
Motor nerve conduction studies
Motor nerve conduction studies were performed at
10 months of age in all the animals used in the study as
previously described61. The sciatic nerve was percuta-
neously stimulated through a pair of needle electrodes
placed at the sciatic notch, by means of single pulses of
0.02 ms duration (Grass S88). The CMAP was recorded
from the tibialis anterior, plantar interossei, and GM
muscles with microneedle electrodes50. All potentials
were ampliﬁed and displayed on a digital oscilloscope
(Tektronix 450 S) at settings appropriate to measure the
amplitude from baseline to the maximal negative peak and
the latency from stimulus to the onset of the ﬁrst negative
deﬂection, to the maximal negative peak and to the end
of the wave. The recording needles were placed under
microscope, guided by anatomical landmarks, to ensure
reproducibility of needle location on all animals. During
the tests, the mouse skin temperature was maintained
between 34 and 36 °C using a thermostat heating pad. The
observers were blinded to the experimental groups.
Electromyography
Electromyography (EMG) recordings of MUAPs were
obtained from the tibialis anterior muscle following a
similar protocol to that previously described62. With the
mice under anesthesia, EMG recordings were obtained in
resting condition and following light noxious stimuli
delivered to the ipsilateral paw to provoke bursts of EMG
activity. Signals were digitized (Powerlab 6 T; ADInstru-
ments) and fed into Chart software for post hoc analysis.
MUAPs were then categorized into small, medium, and
large amplitude as a representation of the three main
types of motor units (S, FR, FF)63, and the amplitude and
percentage of MUAPs from each class were measured.
Von Frey (VF) monoﬁlaments applied to the hind paw
were also used to evoke bursts of EMG activity in the
ipsilateral muscle. Since the force imposed by the ﬁlament
is fairly constant, two different VF monoﬁlaments were
used to evoke responses, one with a known force of 10 g
and 5.07 size and the other with a force of 26 g and a size
of 5.46. The EMG responses recorded from the tibialis
anterior muscle in response to those mechanical stimuli
were recorded and analyzed to measure the area under
the curve of each response using Chart software. At least,
three different responses for each Von Frey ﬁlament were
assessed per mouse.
Immunostaining
Muscle samples were frozen in liquid nitrogen-cooled
isopentane and serial 7 mm sections were cut with a
Leica cryostat (Leica Microsystems, Wetzlar, Germany).
For histological description diaphragm, tibialis anterior,
quadriceps, and heart were stained with haematoxylin
and eosin. Tissue sections were blocked with PBS con-
taining 2% bovine serum albumin and ﬁxed with acetone
at room temperature for 10min. After three washes
with PBS, tissue sections were incubated with rabbit
polyclonal anti-Collagen type VI (Millipore, Billerica, MA),
rabbit anti-Collagen type III (Abcam, Cambridge, UK),
mouse monoclonal anti-embryonic Myosin Heavy Chain
(eMHC) (DSHB, Iowa City, IA), and rabbit polyclonal
CD31 (Abcam). Appropriate Alexa-conjugated secondary
antibodies were used. Fibroblasts from cell proliferation
studies were stained with anti-Ki-67 (Abcam). In brief,
cells were ﬁxed in methanol, washed in PBS, and blocked
with 5% goat serum for 1 h. Anti-Ki-67 (1/1000) was
incubated for 1 h at room temperature (RT) and after
washing steps with PBS, cells were incubated with goat
anti-mouse Alexa594 for 1 h at RT. Positive cells were
quantiﬁed compared with the total number of present
cells. Pictures were taken with Olympus BX51 coupled to a
DP72 camera. Five random pictures were taken per con-
dition per triplicate.
Collagen content quantiﬁcation and muscle ﬁbers
geometric features extraction
Collagen content was labeled and was used to identify
the contours of muscle ﬁbers (darker regions). Aiming
to avoid possible artefacts from the samples we took
regions of interest (ROIs) with circular shape from each
image. The ROIs were selected in regions where the
tissue was not altered or broken. To calculate the collagen
content in the images we took a maximum of three
circular ROIs per image with a diameter of 700 pixels. An
adaptive threshold was used to differentiate collagen and
muscle ﬁbers, binarizing each image depending of theirs
levels of intensity.
To calculate geometric characteristics from the muscle
ﬁbers, we used an unique circular ROI with 2200 pixels
of diameter. For this procedure, we selected 10 circular
ROIs from each type of muscle for each category of
mouse. The segmentation procedure and geometric fea-
tures extraction was similar to the used in previous
publications64. In this case, we only extracted eight geo-
metrical features from the muscle ﬁbers: mean area,
standard deviation area, mean minor axis, mean major
axis, mean relation between axis, standard deviation
relation between axis, mean convex hull, and standard
deviation convex hull. A manual correction step process
was introduced to perfectly complete the identiﬁcation of
the ﬁbers outlines. This was done using Adobe Photoshop
CS6, followed by the ﬁnal segmentation process. This ﬁnal
image was used to extract the eight geometric char-
acteristics from all the cells into the ROI of each image.
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RNA extraction and reverse transcription
Total RNA was extracted from snap frozen ﬁbroblast
pellets and muscle samples of treated, non-treated mdx
and control mice using RNeasy® Micro Kit (Qiagen,
Hilden, Germany) and TRIzol (Invitrogen) respectively,
following manufacturer’s instructions and stored at −80 °C.
Contaminating DNA was digested with DNase I (invi-
trogen). RNA was quantiﬁed using a nanodrop ND-1000
spectrophotometer (Nanodrop Technologies Inc., Wil-
mington, DE, USA) and integrity was checked by 1%
agarose gel electrophoresis. In all, 1 μg of total RNA was
reverse-transcribed to complementary DNA (cDNA)
using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA).
Real-time quantitative PCR (TaqMan) analysis
Real-Time PCR (qPCR) of cDNA obtained from cells
and mouse tissues was performed using the TaqMan®
Universal PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) and a 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA). All mRNA-
speciﬁc FAM-labeled primers/probe were purchased
from Applied Biosystems and detected cDNA from
the following genes: Ctgf (Mm01192933_g1), Pdgfa
(Mm01205760_m1), Pdgfb (Mm00440677_m1), Tgfb1
(Mm01178820_m1), Col1a1 (Mm00801666_g1), Col3a1
(Mm01254476_m1), Fn1 (Mm01256744_m1), Adgre1
(Mm00802529_m1), PDGFA (Hs00964426_m1), CTGF
(Hs01026927_g1), PDGFB (Hs00966522_m1), TGFB1
(Hs00998133_m1), COL1A1 (Hs00164004_m1), COL3A1
(Hs00943809_m1), FN1 (Hs01549976_m1), ACTA
(Hs00426835_g1), MMP9 (Hs00957562_m1), MMP2
(Hs01548727_m1), MMP1 (Hs00899658_m1), TIMP-1
(Hs99999139_m1), TIMP-2 (Hs00234278_m1), ADAM-
12 (Hs01106101_m1), ADAM-17 (Hs01041915_m1),
TP53 (Hs01034249_m1). All the experiments were per-
formed in triplicate. Relative quantiﬁcation was per-
formed using the comparative Ct method and all results
were compared with the control samples for each treat-
ment after normalizing to an endogenous control
(GAPDH (Hs99999905_m1) in the case of human ﬁbro-
blasts and Tuba4a (Mm00849767_s1) in the case of
mice using the Relative Quantiﬁcation Manager software
(Applied Biosystems, Foster City, CA). Data in bar
graphs are presented as mean ± standard deviation of
three independent samples in the case of ﬁbroblasts,
ﬁve in the case of C57 and mdx and seven in the case of
treated mdx mice.
Western blot
Total proteins from diaphragm, tibialis anterior,
and quadriceps muscles were extracted in radio-
immunoprecipitation assay lysis buffer (Sigma, St. Louis,
MO) supplemented with 1% protease inhibitor cocktail
(Roche, Indianapolis, IN) and 1% phosphatase inhibitor
cocktail (Roche). The protein levels were measured
using the bicinchoninic acid protein assay (Thermo-
scientiﬁc, Rockford, IL). Protein samples (50 μg) were
denatured and separated on 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis before transfer onto
a polyvinylidene diﬂuoride membrane and blocked with
casein (Thermoﬁsher, Rockford, IL). The blots were
probed using different rabbit polyclonal anti-Collagen I
antibodies (Abcam, Cambridge, UK). The blots were
further incubated with secondary antibodies conjugated
to ﬂuorophores (LI-COR, Lincoln, Nebraska) and visua-
lized using an Odyssey Imaging System (LI-COR). Protein
levels were expressed relative to α-tubulin. Mouse
monoclonal anti-α-tubulin antibody was purchased from
Sigma (St. Louise, MO).
Statistics
We used Student’s t test to compare quantitative mea-
sures between samples and analysis of variance to study
repeated measures. Statistical signiﬁcance was obtained
at p < 0.05. Statistical studies were performed with SPSS®
Statistics software version 21 from IBM® and graphics
were developed using GraphPad Prism 5.01 software
(La Jolla, CA).
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